Elevation Oncology (ELEV) Competitors $0.35 +0.01 (+2.91%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$0.35 0.00 (0.00%) As of 05/2/2025 05:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ELEV vs. ALTS, MGNX, EXOZ, ANIX, TCRX, KYTX, VOR, BDTX, ENTX, and HLVXShould you be buying Elevation Oncology stock or one of its competitors? The main competitors of Elevation Oncology include Janone (ALTS), MacroGenics (MGNX), Exozymes (EXOZ), Anixa Biosciences (ANIX), TScan Therapeutics (TCRX), Kyverna Therapeutics (KYTX), Vor Biopharma (VOR), Black Diamond Therapeutics (BDTX), Entera Bio (ENTX), and HilleVax (HLVX). These companies are all part of the "pharmaceutical products" industry. Elevation Oncology vs. Janone MacroGenics Exozymes Anixa Biosciences TScan Therapeutics Kyverna Therapeutics Vor Biopharma Black Diamond Therapeutics Entera Bio HilleVax Janone (NASDAQ:ALTS) and Elevation Oncology (NASDAQ:ELEV) are both small-cap finance companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, community ranking, risk, media sentiment, valuation, dividends and profitability. Do insiders and institutionals believe in ALTS or ELEV? 6.3% of Janone shares are owned by institutional investors. Comparatively, 83.7% of Elevation Oncology shares are owned by institutional investors. 4.9% of Janone shares are owned by insiders. Comparatively, 8.1% of Elevation Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has better earnings & valuation, ALTS or ELEV? Janone has higher revenue and earnings than Elevation Oncology. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJanone$12.53M7.84-$7.81MN/AN/AElevation OncologyN/AN/A-$45.70M-$0.81-0.43 Which has more risk and volatility, ALTS or ELEV? Janone has a beta of 2.14, meaning that its stock price is 114% more volatile than the S&P 500. Comparatively, Elevation Oncology has a beta of 1.65, meaning that its stock price is 65% more volatile than the S&P 500. Is ALTS or ELEV more profitable? Elevation Oncology's return on equity of -59.73% beat Janone's return on equity.Company Net Margins Return on Equity Return on Assets JanoneN/A -2,940.01% -39.81% Elevation Oncology N/A -59.73%-40.05% Do analysts recommend ALTS or ELEV? Elevation Oncology has a consensus target price of $3.39, suggesting a potential upside of 867.35%. Given Elevation Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Elevation Oncology is more favorable than Janone.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Janone 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Elevation Oncology 0 Sell rating(s) 7 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.30 Does the MarketBeat Community believe in ALTS or ELEV? Elevation Oncology received 39 more outperform votes than Janone when rated by MarketBeat users. CompanyUnderperformOutperformJanoneN/AN/AElevation OncologyOutperform Votes3966.10% Underperform Votes2033.90% Does the media refer more to ALTS or ELEV? In the previous week, Elevation Oncology had 1 more articles in the media than Janone. MarketBeat recorded 1 mentions for Elevation Oncology and 0 mentions for Janone. Elevation Oncology's average media sentiment score of 0.96 beat Janone's score of 0.94 indicating that Elevation Oncology is being referred to more favorably in the news media. Company Overall Sentiment Janone Positive Elevation Oncology Positive SummaryElevation Oncology beats Janone on 9 of the 13 factors compared between the two stocks. Get Elevation Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for ELEV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELEV vs. The Competition Export to ExcelMetricElevation OncologyBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.73M$2.97B$5.56B$8.04BDividend YieldN/A1.87%5.09%4.22%P/E Ratio-0.4330.5222.6918.83Price / SalesN/A494.70404.28106.72Price / CashN/A168.6838.1834.62Price / Book0.273.216.794.33Net Income-$45.70M-$72.35M$3.22B$247.97M7 Day Performance-6.89%13.48%3.37%3.18%1 Month Performance35.40%12.33%6.95%8.13%1 Year Performance-90.54%-23.51%16.13%5.01% Elevation Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELEVElevation Oncology2.6331 of 5 stars$0.35+2.9%$3.39+867.3%-90.8%$20.73MN/A-0.4340ALTSJanoneN/A$5.56+8.0%N/AN/A$89.40M$12.53M0.00170MGNXMacroGenics4.0094 of 5 stars$1.39+10.3%$7.38+430.6%-88.5%$87.70M$148.34M-0.88430Upcoming EarningsNews CoveragePositive NewsGap UpEXOZExozymesN/A$10.47-3.4%N/AN/A$87.61MN/A0.0029ANIXAnixa Biosciences2.235 of 5 stars$2.69-1.1%$9.00+234.6%-6.4%$86.61M$210,000.00-6.905TCRXTScan Therapeutics3.7708 of 5 stars$1.53+6.3%$9.33+510.0%-81.5%$86.58M$2.82M-1.44100Positive NewsKYTXKyverna Therapeutics1.8164 of 5 stars$1.99+7.0%$18.33+821.3%-84.8%$86.01M$7.03M-0.5796News CoverageGap DownVORVor Biopharma2.5829 of 5 stars$0.69+5.6%$8.86+1,190.4%-62.4%$85.70MN/A-0.42140News CoverageGap UpBDTXBlack Diamond Therapeutics3.5426 of 5 stars$1.49+3.5%$14.60+879.9%-73.0%$84.43MN/A-1.1290Upcoming EarningsNews CoveragePositive NewsENTXEntera Bio1.9869 of 5 stars$1.84+2.8%$10.00+443.5%+12.9%$83.58M$181,000.00-7.0820Upcoming EarningsNews CoverageHLVXHilleVax2.8007 of 5 stars$1.66-1.8%$3.00+80.7%-86.0%$83.23MN/A-0.5420Upcoming EarningsNews Coverage Related Companies and Tools Related Companies ALTS Alternatives MGNX Alternatives EXOZ Alternatives ANIX Alternatives TCRX Alternatives KYTX Alternatives VOR Alternatives BDTX Alternatives ENTX Alternatives HLVX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELEV) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredMassive red flag about American consumerWhy is the U.S. Dollar suddenly crashing? Pundits on either side of the aisle have been warning that the U....Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elevation Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elevation Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ELEV Stock Free ELEV Stock Alerts